Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Viability of systemic sclerosis dermal fibroblasts in the presence or absence of bosentan, which was evaluated by trypan blue exclusion test

From: Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1

Duration of treatment (h) Bosentan (μM)
0 10 20 40
0 96.5 ± 0.05 98.8 ± 0.24 96.3 ± 0.70 97.3 ± 1.52
24 97.3 ± 1.13 97.8 ± 1.13 97.6 ± 1.68 96.3 ± 0.72
48 95.6 ± 0.64 96.2 ± 0.55 96.8 ± 0.25 95.1 ± 0.18
  1. The impact of bosentan on cell viability was evaluated by trypan blue exclusion test. The percentage of cell viability was calculated according to the following formula: % cell viability = (viable cell count/total cell count) × 100. Data are expressed as the mean ± SD of results in three independent experiments.